Biomarin Pharmaceutical is a biotechnology business based in the US. Biomarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $62.06 – a decrease of 1.93% over the previous week. Biomarin Pharmaceutical employs 3,040 staff and has a trailing 12-month revenue of around $2.9 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $62.06 |
|---|---|
| 52-week range | $52.93 - $94.85 |
| 50-day moving average | $66.66 |
| 200-day moving average | $70.97 |
| Wall St. target price | $96.87 |
| PE ratio | 28.3756 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $2.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $62.03 from 2025-05-02
| 1 week (2025-04-28) | -1.51% |
|---|---|
| 1 month (2025-04-04) | 2.94% |
| 3 months (2025-02-06) | -3.59% |
| 6 months (2024-11-06) | -6.23% |
| 1 year (2024-05-06) | -24.45% |
|---|---|
| 2 years (2023-05-05) | -35.81% |
| 3 years (2022-05-05) | 81.97 |
| 5 years (2020-05-05) | 93.19 |
Valuing Biomarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biomarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biomarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Biomarin Pharmaceutical shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Biomarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4356. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biomarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biomarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $666.5 million.
The EBITDA is a measure of a Biomarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.9 billion |
|---|---|
| Operating margin TTM | 34.42% |
| Gross profit TTM | $2.3 billion |
| Return on assets TTM | 5.15% |
| Return on equity TTM | 8.05% |
| Profit margin | 14.96% |
| Book value | $29.66 |
| Market Capitalization | $12 billion |
TTM: trailing 12 months
We're not expecting Biomarin Pharmaceutical to pay a dividend over the next 12 months.
Over the last 12 months, Biomarin Pharmaceutical's shares have ranged in value from as little as $52.93 up to $94.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomarin Pharmaceutical's is 0.301. This would suggest that Biomarin Pharmaceutical's shares are less volatile than average (for this exchange).
BioMarin Pharmaceutical Inc. , a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U. S.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.